Home › Funds › Rosalind Advisors, Inc. › CLDX

Rosalind Advisors, Inc. position in CLDX

CELLDEX THERAPEUTICS INC NEW · Health Care

Rosalind Advisors, Inc. reported holding 200,000 shares of CLDX (CELLDEX THERAPEUTICS INC NEW) in its Q2 2026 13F filing — a position valued at US$7.4M, representing 2.77% of its reported portfolio and ranking #12 among its reported holdings. Rosalind Advisors, Inc. has disclosed CLDX holdings in 2 of the last 2 reported quarters, going back to Q1 2026.

Latest position (Q2 2026)200.00K sh
Reported value held$7.44M
Portfolio Weight2.77%
First reportedQ1 2026
Last changeReduce
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Rosalind Advisors, Inc.'s CLDX position evolved

Rosalind Advisors, Inc. first disclosed a stake in CLDX in Q1 2026 at 330,000 shares (US$10.5M). Across 2 filings, Rosalind Advisors, Inc. increased the stake 0 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 200,000 shares valued at US$7.4M — a reduction of -130,000 shares quarter over quarter.. Notable position changes include a 39% trim in Q2 2026 (shares fell 13% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q1 2026 330.00K $10.47M New
Q2 2026 200.00K $7.44M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About CLDX and 13F data

CLDX (CELLDEX THERAPEUTICS INC NEW) is a Health Care company. 44 other funds we track also report a position in CLDX — the largest reported positions include Kynam Capital Management, LP (US$198.1M), Deep Track Capital, LP (US$109.4M), Logos Global Management LP (US$78.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding CLDX

All CLDX fund holders →

FAQ

How long has Rosalind Advisors, Inc. held CLDX?

Rosalind Advisors, Inc. has disclosed CLDX holdings in 2 of the last 2 reported quarters, going back to Q1 2026.

What is Rosalind Advisors, Inc.'s current position in CLDX?

As of Q2 2026, Rosalind Advisors, Inc. holds 200.00K shares of CLDX (CELLDEX THERAPEUTICS INC NEW), valued at $7.44M, representing 2.77% of its reported portfolio and ranking #12.

Has Rosalind Advisors, Inc. been buying or selling CLDX?

In the latest 13F filing (Q2 2026), Rosalind Advisors, Inc. reduced its position in CLDX.

Which other funds hold CLDX?

Other major institutional holders of CLDX include Kynam Capital Management, LP, Deep Track Capital, LP, Logos Global Management LP, among 44 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.